The global bispecific antibodies market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). The major factor attributed to the market growth includes the rising prevalence of cancer all over the globe. Presently, there are above 300 drug candidates available for the bispecific antibodies for cancer. Majority of these drug candidates are in their pre-clinical or clinical trial stages. Various medical technology providers and drug developers operating within the global bispecific antibodies for cancer market have entered into strategic collaborations together by signing numerous licensing agreements. These efforts are undertaken to advance the development of promising pipeline drug candidates with unique pharmacological and biological properties in the global bispecific antibodies market.
To Request a Sample of our Report on Bispecific Antibodies Market: https://www.omrglobal.com/request-sample/bispecific-antibodies-market
Cancer had proven to be one of the most chronic diseases globally which is further responsible for a large number of fatalities all over the globe. Therefore, as a measure to control this situation and avoid the further prevalence of cancer, the global bispecific antibodies market is likely to grow. Due to this, substantial growth in the number of clinical trials aimed towards the development of potent and advanced bispecific drugs during the past decade has acted favorably for the global bispecific antibodies market. These trials have made these drugs a popular as well as a promising candidate for enhanced treatment of various rare medical conditions, especially a variety of cancers. Presently, Blincyto, Hemlibra and Rybrevant are available in the commercial market, which are further likely to grow in the forecast period.
Market Coverage
- The market number available for – 2022-2028
- Base year- 2021
- Forecast period- 2022-2028
Segment Covered-
- By Drug Type
- By Indication
- By Distribution Channel
Regions covered-
- North America
- Europe
- Asia-Pacific
- Rest of the World
Competitive Landscape: Sanofi S.A., AbbVie Inc., and Pfizer Inc., among others.
A full Report Bispecific Antibodies Market is Available @ https://www.omrglobal.com/industry-reports/bispecific-antibodies-market
Global Bispecific Antibodies Market Report by Segment
By Drug Type
- Blinatumomab
- Catumaxomab
- Duligotumab
By Indication
- Cancer
- Infectious Disease
- Inflammatory and Autoimmune Disorders
- CNS Disorders
By End-User
- Hospital Pharmacies
- Retail Pharmacies
- Drug Stores
- Online Pharmacies
Global Bispecific Antibodies Market Report by Region
North America
- United States
- Canada
Europe
- UK
- Germany
- Spain
- France
- Italy
- Rest of Europe
Asia-Pacific
- India
- China
- Japan
- South Korea
- Rest of APAC
Rest of the World
- Latin America
- Middle East & Africa
Reasons to buy from us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404
